Results 21 to 30 of about 76,606 (312)

Microalbuminuria

open access: yesClinical and Experimental Hypertension, 2004
The capacity of microalbuminuria to predict an increased cardiovascular and renal risk is well established in diabetic patients, as well as in essential hypertensive patients and in general population. Detection of microalbuminuria could then be relevant to select specific therapeutic strategies for reducing or preventing cardiovascular events in ...
J, Segura, L M, Ruilope, J L, Rodicio
openaire   +2 more sources

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

open access: yesAmerican Society of Nephrology. Clinical Journal, 2019
BACKGROUND AND OBJECTIVES The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidal mineralocorticoid receptor blocker
S. Ito   +4 more
semanticscholar   +1 more source

Perbandingan Kadar Mikroalbuminuria Pada Stroke Infark Aterotrombotik Dengan Faktor Risiko Hipertensi dan Pasien Hipertensi

open access: yesMajalah Kedokteran Bandung, 2009
Microalbuminuria is a marker of vascular damage in glomerular system caused by vascular risk factors : hypertension, diabetes mellitus, lipid profile, smoking, older age, genetic and atherosclerosis.
S A Putri   +3 more
doaj   +1 more source

Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis [PDF]

open access: yes, 2015
OBJECTIVE: Glycemic variability is emerging as a measure of glycemic control, which may be a reliable predictor of complications. This systematic review and meta-analysis evaluates the association between HbA1c variability and micro- and macrovascular ...
Catherine Gorst   +18 more
core   +1 more source

Synthetic molecular recognition nanosensor paint for microalbuminuria

open access: yesNature Communications, 2019
Microalbuminuria is an important clinical marker of several cardiovascular, metabolic, and other diseases such as diabetes, hypertension, atherosclerosis, and cancer.
Januka Budhathoki-Uprety   +10 more
semanticscholar   +1 more source

Dietary interventions to contrast the onset and progression of diabetic nephropathy. a critical survey of new data [PDF]

open access: yes, 2017
This article is a critical overview of recent contributions on the dietary corrections and the foods that have been claimed to delay or hinder the onset of diabetic nephropathy (DN) and its progression to end-stage renal disease.
Iacobini, Carla   +3 more
core   +1 more source

Risk factors associated with microalbuminuria in children and adolescents with diabetes in Bangladesh

open access: yesIndian Journal of Endocrinology and Metabolism, 2018
Introduction: Diabetic nephropathy is leading cause of morbidity and mortality of type 1 diabetes mellitus (DM). Microalbuminuria is the first clinical sign of nephropathy.
Bedowra Zabeen   +4 more
doaj   +1 more source

Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. [PDF]

open access: yes, 2016
ObjectiveTo compare different blood pressure (BP) levels in their association with the risk of renal outcomes in type 1 diabetes and to determine whether an intensive glycemic control strategy modifies this association.Research design and methodsWe ...
Gitelman, Stephen E   +5 more
core   +2 more sources

Screening for microalbuminuria [PDF]

open access: yesKidney International, 2005
Contains fulltext : 48389.pdf (Publisher’s version ) (Open Access)
Hilbrands, L.B.   +2 more
openaire   +3 more sources

Microalbuminuria - A better marker in hypertensive disorders of pregnancy

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2015
To assess the role of microalbuminuria in pre-eclampsia (PE) as a diagnostic marker, we studied 40 PE cases and 40 normotensive controls at 24 ± 4 weeks of gestation in women 20-35 years of age.
Ruby P Babu   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy